BioSpace News Archive

Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 202,290 shares of common stock and restricted stock units for 61,145 shares with a grant date of January 31, 2023 for nine new employees.

Mersana Therapeutics, Inc. announced that on March 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of restricted stock unit awards to acquire an aggregate of 44,930 shares of its common stock, to four new employees whose employment commenced in February 2023.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 27,550 restricted stock units of Arcutis’ common stock to four newly hired employees.

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents per share on the $.10 par value common stock of the company.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 17 new employees.

Summit Therapeutics Inc. announced the successful closing of its fully-subscribed $500 million rights offering.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia (TD) with INGREZZA® (valbenazine) capsules in older (≥55 years) and elderly (≥65 years) patients from two studies (KINECT™ 3-extension and KINECT™ 4).

NanoVibronix, Inc today announced that on February 28, 2023, the Company received official notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.

Aditxt, Inc. announces it has retained Riverside Management Group, LLC, a merchant banking firm providing investment banking advisory services, to support the Company’s ongoing growth and revenue generating plans for its subsidiary Pearsanta, Inc.

LumiraDx Limited will be presenting at the Raymond James Institutional Investors Conference on Tuesday, March 7th, 2023 at 4:35pm ET. Webcast link below.